948 related articles for article (PubMed ID: 33757520)
21. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
23. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts.
Muro S; Sugiura H; Darken P; Dorinsky P
Respir Res; 2021 Jun; 22(1):187. PubMed ID: 34182998
[TBL] [Abstract][Full Text] [Related]
25. The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN).
Skloot GS; Guasconi A; Lavon BR; Georges G; De Backer W; Galkin D; Cortellini M; Panni I; Bates JHT
Respir Res; 2023 Oct; 24(1):244. PubMed ID: 37803368
[TBL] [Abstract][Full Text] [Related]
26. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Reisner C; Fabbri LM; Kerwin EM; Fogarty C; Spangenthal S; Rabe KF; Ferguson GT; Martinez FJ; Donohue JF; Darken P; St Rose E; Orevillo C; Strom S; Fischer T; Golden M; Dwivedi S
Respir Res; 2017 Jan; 18(1):8. PubMed ID: 28061907
[TBL] [Abstract][Full Text] [Related]
27. Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.
Singh D; Scuri M; Collarini S; Vezzoli S; Mariotti F; Muraro A; Acerbi D
Int J Chron Obstruct Pulmon Dis; 2017; 12():2001-2014. PubMed ID: 28744115
[TBL] [Abstract][Full Text] [Related]
28. The efficacy of extrafine beclomethasone dipropionate-formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study.
Singh D; Vezzoli S; Petruzzelli S; Papi A
Int J Chron Obstruct Pulmon Dis; 2017; 12():3263-3271. PubMed ID: 29138555
[TBL] [Abstract][Full Text] [Related]
29. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
[TBL] [Abstract][Full Text] [Related]
31. Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study.
Voorham J; Baldi S; Santoro L; Kerkhof M; Contoli M; Fabbri LM; Kerstjens HAM; Luis López-Campos J; Roche N; Singh D; Vogelmeier CF; Price DB
Int J Chron Obstruct Pulmon Dis; 2020; 15():2739-2750. PubMed ID: 33149571
[TBL] [Abstract][Full Text] [Related]
32. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
Martinez FJ; Rabe KF; Ferguson GT; Fabbri LM; Rennard S; Feldman GJ; Sethi S; Spangenthal S; Gottschlich GM; Rodriguez-Roisin R; Arora S; Siler TM; Siddiqui S; Darken P; Fischer T; Maes A; Golden M; Orevillo C; Reisner C
Chest; 2017 Feb; 151(2):340-357. PubMed ID: 27916620
[TBL] [Abstract][Full Text] [Related]
34. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.
Sethi S; Kerwin E; Watz H; Ferguson GT; Mroz RM; Segarra R; Molins E; Jarreta D; Garcia Gil E
Int J Chron Obstruct Pulmon Dis; 2019; 14():667-682. PubMed ID: 30962681
[TBL] [Abstract][Full Text] [Related]
35. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
36. The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol.
Richeldi L; Piraino A; Macagno F; Micarelli G; Ingrassia E
Int J Chron Obstruct Pulmon Dis; 2021; 16():159-166. PubMed ID: 33536751
[TBL] [Abstract][Full Text] [Related]
37. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
Kerwin EM; Siler TM; Arora S; Darken P; Rose E; Reisner C
Int J Chron Obstruct Pulmon Dis; 2018; 13():1483-1494. PubMed ID: 29773947
[TBL] [Abstract][Full Text] [Related]
38. Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.
Dhungana S; Criner GJ
Int J Chron Obstruct Pulmon Dis; 2017; 12():2307-2312. PubMed ID: 28814858
[TBL] [Abstract][Full Text] [Related]
39. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging.
De Backer J; Vos W; Vinchurkar S; Van Holsbeke C; Poli G; Claes R; Salgado R; De Backer W
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):88-99. PubMed ID: 25004168
[TBL] [Abstract][Full Text] [Related]
40. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]